NASDAQ:ADRO - Aduro Biotech Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Aduro Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADRO

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Aduro Biotech in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for ADRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Aduro Biotech. This rating has held steady since July 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2020HC WainwrightReiterated RatingBuy$3.75High
6/5/2020OppenheimerInitiated CoverageHoldHigh
6/2/2020HC WainwrightBoost Price TargetBuy$3.75 ➝ $4.00Low
5/4/2020OppenheimerReiterated RatingHoldHigh
1/31/2020SVB LeerinkBoost Price TargetOutperform$3.00 ➝ $7.00High
1/9/2020CowenDowngradeOutperform ➝ Market PerformHigh
12/18/2019HC WainwrightLower Price TargetBuy$7.00 ➝ $4.00High
12/18/2019William BlairDowngradeOutperform ➝ Market PerformHigh
8/2/2019CowenReiterated RatingBuyHigh
6/3/2019CIBCReiterated RatingOutperform ➝ Market PerformHigh
6/3/2019OppenheimerDowngradeOutperform ➝ Market PerformHigh
5/8/2019CowenReiterated RatingBuyHigh
4/15/2019SVB LeerinkReiterated RatingOutperform ➝ Outperform$9.00High
3/19/2019OppenheimerReiterated RatingBuyLow
12/19/2018HC WainwrightReiterated RatingBuy$8.30High
11/13/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$30.00 ➝ $10.00High
11/12/2018OppenheimerSet Price TargetBuy$10.00Low
11/12/2018HC WainwrightSet Price TargetBuy$8.00Low
10/31/2018CowenReiterated RatingBuyHigh
10/30/2018OppenheimerSet Price TargetBuy$10.00High
10/3/2018William BlairReiterated RatingBuyLow
10/2/2018HC WainwrightSet Price TargetBuy$8.00High
8/2/2018Canaccord GenuityReiterated RatingBuy$30.00High
8/2/2018Bank of AmericaLower Price TargetUnderperform ➝ Underperform$8.00 ➝ $6.00High
8/2/2018HC WainwrightSet Price TargetBuy$10.00High
5/3/2018HC WainwrightSet Price TargetBuy$10.00High
4/26/2018HC WainwrightSet Price TargetBuy$10.00Medium
3/5/2018Cantor FitzgeraldReiterated RatingBuy$15.00Low
3/2/2018Bank of AmericaLower Price TargetUnderperform ➝ Underperform$9.00 ➝ $8.00Low
3/2/2018Canaccord GenuityReiterated RatingBuyLow
3/2/2018HC WainwrightSet Price TargetBuy$10.00High
2/21/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$15.00High
1/16/2018HC WainwrightSet Price TargetBuy$10.00High
12/19/2017HC WainwrightSet Price TargetBuy$10.00Low
12/14/2017Canaccord GenuitySet Price TargetBuy$30.00Medium
12/13/2017OppenheimerLower Price TargetOutperform$15.00 ➝ $13.00High
12/13/2017HC WainwrightLower Price TargetBuy ➝ Buy$18.00 ➝ $9.50Low
12/11/2017OppenheimerSet Price TargetBuy$15.00High
11/1/2017HC WainwrightSet Price TargetBuy$18.00N/A
10/30/2017OppenheimerInitiated CoverageBuy$15.00N/A
10/17/2017HC WainwrightSet Price TargetBuy$18.00N/A
10/2/2017William BlairReiterated RatingOutperformHigh
9/27/2017HC WainwrightReiterated RatingBuy$18.00Medium
8/3/2017Canaccord GenuitySet Price TargetBuy$30.00Low
8/3/2017HC WainwrightSet Price TargetBuy$18.00High
7/18/2017CowenInitiated CoverageOutperformLow
5/3/2017Canaccord GenuityReiterated RatingBuy$30.00Medium
5/1/2017HC WainwrightInitiated CoverageBuy$18.00Low
5/1/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$18.00Low
3/27/2017Canaccord GenuitySet Price TargetBuy$30.00Low
3/7/2017FBR & Co.Reiterated RatingBuy$23.00N/A
3/7/2017Roth CapitalReiterated RatingBuy$17.00N/A
3/2/2017Canaccord GenuitySet Price TargetBuy$30.00N/A
1/19/2017Canaccord GenuitySet Price TargetBuy$30.00N/A
12/6/2016Canaccord GenuitySet Price TargetBuy$30.00N/A
11/25/2016Roth CapitalReiterated RatingBuy$20.00N/A
11/22/2016FBR & Co.Reiterated RatingBuyN/A
11/21/2016Canaccord GenuitySet Price TargetBuy$30.00N/A
11/14/2016FBR & Co.Reiterated RatingOutperform$20.00N/A
10/27/2016Roth CapitalReiterated RatingBuy$22.00 ➝ $20.00N/A
10/26/2016FBR & Co.Reiterated RatingOutperform$22.00 ➝ $20.00N/A
10/24/2016Canaccord GenuitySet Price TargetBuy$30.00N/A
10/24/2016SVB LeerinkSet Price TargetBuy$14.00N/A
(Data available from 9/27/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aduro Biotech logo
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $10.93
Low: $2.28
High: $14.60

52 Week Range

Now: N/A

Volume

171,500 shs

Average Volume

162,237 shs

Market Capitalization

$236.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Aduro Biotech?

The following Wall Street sell-side analysts have issued stock ratings on Aduro Biotech in the last twelve months: Zacks Investment Research.
View the latest analyst ratings for ADRO.

What is the current price target for Aduro Biotech?

0 Wall Street analysts have set twelve-month price targets for Aduro Biotech in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aduro Biotech in the next year.
View the latest price targets for ADRO.

What is the current consensus analyst rating for Aduro Biotech?

Aduro Biotech currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ADRO.

How do I contact Aduro Biotech's investor relations team?

Aduro Biotech's physical mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company's listed phone number is (206) 485-7051 and its investor relations email address is [email protected] The official website for Aduro Biotech is www.aduro.com.